Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of combination weekly bortezomib (Velcade) and docetaxel (Taxotere) in patients with recurrent and/ or metastatic head and neck squamous cell carcinoma (HNSCC).

Trial Profile

Phase II trial of combination weekly bortezomib (Velcade) and docetaxel (Taxotere) in patients with recurrent and/ or metastatic head and neck squamous cell carcinoma (HNSCC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2011

At a glance

  • Drugs Bortezomib (Primary) ; Docetaxel
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 01 Apr 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 25 Nov 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 16 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top